10 terminated. 10 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Terminated 10 |
| Phase 2 | 1 | Terminated 1 |
Follow Panuveitis: new trials by email Literature Review of Panuveitis trials Research Report on Panuveitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert Sham Injector, FAI Insert - Uveitis, Uveitis, Posterior | Phase 3 | Terminated | EyePoint Pharmaceuticals, Inc. | 12 | 2021-10-13 | 2024-12-19 |
| Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis Placebo, Gevokizumab - Behcet's Disease Uveitis | Phase 3 | Terminated | XOMA (US) LLC | 4 | 2014-11-01 | 2015-12-29 |
| Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X) Gevokizumab - Chronic Uveitis | Phase 3 | Terminated | Institut de Recherches Internationales Servier | 71 | 2014-08-01 | 2020-01-03 |
| An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data Dose 2 gevokizumab - Uveitis | Phase 3 | Terminated | XOMA (US) LLC | 69 | 2014-03-01 | 2015-10-16 |
| Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment Placebo, Dose 1 gevokizumab, Dose 2 gevokizumab - Uveitis | Phase 3 | Terminated | XOMA (US) LLC | 281 | 2012-10-01 | 2016-07-12 |
| Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis Placebo, Dose 1 gevokizumab, Dose 2 gevokizumab - Uveitis | Phase 3 | Terminated | XOMA (US) LLC | 200 | 2012-08-01 | 2016-04-08 |
| Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis AIN457, Placebo - Non-infectious Uveitis | Phase 3 | Terminated | Novartis Pharmaceuticals | 86 | 2010-08-01 | 2016-01-14 |
| Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis AIN457, Placebo - Uveitis | Phase 3 | Terminated | Novartis Pharmaceuticals | 30 | 2010-04-01 | 2015-11-03 |
| Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis AIN457, Placebo - Non-infectious Uveitis | Phase 3 | Terminated | Novartis Pharmaceuticals | 125 | 2010-02-01 | 2015-11-05 |
| A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis Dexamethasone - Anterior Uveitis | Phase 2 / Phase 3 | Terminated | Allergan | 5 | 2006-05-01 | 2011-05-30 |
Uveitis (9) · Uveitis, Intermediate (8) · Uveitis, Posterior (8) · Behcet Syndrome (1) · Cardiovascular Diseases (1) · Dermatitis (1) · Myocardial Infarction (1) · Psoriasis (1) · Uveitis, Anterior (1)
Eye Diseases (10) · Uveal Diseases (10) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Vascular Diseases (2) · Cardiovascular Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Heart Diseases (1) · Hereditary Autoinflammatory Diseases (1) · Infarction (1) · Ischemia (1) · Mouth Diseases (1) · Myocardial Ischemia (1)
secukinumab (3) · gevokizumab (2) · Bulk Drugs (1) · Dexamethasone (1)
XOMA (US) LLC (4) · Novartis Pharmaceuticals (3) · Allergan (1) · EyePoint Pharmaceuticals, Inc. (1) · Institut de Recherches Internationales Servier (1)
United States (9) · Germany (6) · Spain (6) · United Kingdom (6) · Israel (5) · Brazil (4) · France (4) · Turkey (Türkiye) (4) · Australia (3) · Greece (3) · India (3) · Italy (3) · Portugal (3) · Switzerland (3) · Taiwan (3)
2009 (3)